Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

Where Eli Lilly starts to really separate itself from Novo Nordisk is in other markets. For example, over the summer Lilly's Alzheimer's drug received approval from the FDA. More recently ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

MariTide, positioned as a monthly alternative to weekly injections offered by competitors Novo Nordisk NVO and Eli Lilly, ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

There has been no update from the FTC on its review of the deal since then. Novo Nordisk faces competition from U.S. rival ...

Some of these medications include Novo Nordisk's (NYSE: NVO) Ozempic, Wegovy, Rybelsus, and Saxenda, and Eli Lilly's (NYSE: LLY) Mounjaro and Zepbound. Below, I'll dig into which pharmaceutical ...